Risk Minimisation materials for Aubagio (teriflunomide) film-coated tablets: Education/discussion guide for Healthcare Professionals and Patient Alert Card -

Risk Minimisation materials for Aubagio (teriflunomide) film-coated tablets: Education/discussion guide for Healthcare Professionals and Patient Alert Card
Information type: Safety alerts
Source: Glenmark Pharmaceuticals Europe Ltd
Specialities: Neurological disorders
Summary
At first prescription, the prescriber should discuss risks of hepatic and haematological adverse effects, risk of serious infections, hypertension, and in women of childbearing potential, exclude pregnancy and emphasise need for effective contraception before and during treatment
UKMi comment
The prescriber/healthcare professional (HCP) should also provide the Patient Card, which contains important safety information the patient needs to be aware of when receiving treatment with teriflunomide.
Related links: Patient Alert Card